MDS Nordion and University of Ottawa Heart Institute Launch Molecular Imaging Centre of Excellence to Advance Innovative Cardiol
04 Juin 2007 - 3:00PM
PR Newswire (US)
MDS Nordion Expands Imaging and Drug Development Capabilities
OTTAWA, June 4 /PRNewswire-FirstCall/ -- MDS Nordion, a leading
global provider of medical isotopes and radiopharmaceuticals used
in molecular imaging, announced today that it is collaborating with
the University of Ottawa Heart Institute, Canada's largest
cardiovascular health centre, to establish a Molecular Imaging
Centre of Excellence to advance cardiology research. Molecular
imaging is an emerging technology that differs from traditional
medical imaging as it examines changes at the molecular level
within the body to support early disease detection and treatment
assessment. MDS Nordion will invest an estimated US $2.2 million in
this new centre, which will be equipped with a research and
development radiochemistry laboratory to support cardiology
research. This collaboration represents a unique opportunity to
expand MDS Nordion's molecular imaging business. Set to open in
late 2007 on the Institute's campus, this new centre will enable
the two organizations to collaborate on joint cardiology research
using the latest in molecular imaging technology. Through this
collaboration, MDS Nordion will also provide its innovative
molecular imaging services to large pharmaceutical companies to
help them bring promising new drugs to market faster and with less
cost. For patients, molecular imaging technology can play an
important role in advancing the promise of personalized medicine
within the medical community. In addition to helping medical
practitioners detect disease earlier, this technology can help
physicians to better determine the best treatment for each patient
and to monitor their progress throughout treatment. "We are making
a major commitment to innovation with this new centre that can
ultimately make a profound difference in the lives of cardiac
patients," said Steve West, president of MDS Nordion. "By joining
forces with the University of Ottawa Heart Institute, we have a
phenomenal opportunity to share world-class knowledge, equipment
and advanced technology to improve cardiac care." "This
collaboration will enable the Heart Institute to remain at the
forefront of cardiovascular care, education and research," said Dr.
Terrence Ruddy, Chief of Cardiology, University of Ottawa Heart
Institute. "The Centre is an important addition that will add a new
dimension to our research infrastructure. We expect that the
research capabilities and opportunities fuelled by this technology
will provide a major step forward in combating and ultimately
eradicating heart disease." Cardiovascular disease is the number
one killer in the United States and Canada. In the United States,
cardiovascular disease is responsible for 36.3 percent of all
deaths in 2004, and over 79 million Americans have one or more
forms of the disease. In 2001, heart disease accounted for 33
percent of all deaths in men and 35 percent of all deaths in women
in Canada, according to the Canadian Health Network. About MDS
Nordion MDS Nordion (http://www.mdsnordion.com/) is a world leader
in medical isotopes, radiation and related technologies. It is a
business unit of MDS Inc. (TSX:MDS)(NYSE:MDZ). MDS Inc. is a global
life sciences company that provides market-leading products and
services for the development of drugs and diagnosis and treatment
of disease. We are a leading global provider of pharmaceutical
contract research, medical isotopes for molecular imaging,
radiotherapeutics, and analytical instruments. MDS Inc. has more
than 6,200 highly skilled people in 28 countries. Find out more at
http://www.mdsinc.com/ or by calling 1-888-MDS-7222, 24 hours a
day. About the University of Ottawa Heart Institute The University
of Ottawa Heart Institute is Canada's largest and foremost
cardiovascular health centre dedicated to understanding, treating
and preventing heart disease. The Heart Institute delivers
high-tech care with a personal touch, shapes the way cardiovascular
medicine is practiced, and revolutionizes cardiac treatment and
understanding. It builds knowledge through research and translates
discoveries into advanced care. The University of Ottawa Heart
Institute serves the local, national and international community
and is pioneering a new era in heart health. For more information,
visit http://www.ottawaheart.ca/. /NOTE TO PHOTO EDITORS: A photo
accompanying this release is available on the CNW Photo Network and
archived at http://photos.newswire.ca/. Additional archived images
are also available on the CNW Photo Archive website at
http://photos.newswire.ca/. Images are free to accredited members
of the media/ DATASOURCE: MDS Nordion CONTACT: Media: Tamra
Benjamin, Director, External and Marketing Communications, MDS
Nordion, (613) 697-5815, ; Marlene Orton, Senior Manager, Public
Affairs, University of Ottawa Heart Institute, (613) 761-4427, ;
Investors: Sharon Mathers, Senior Vice-President, Investor
Relations and External Communications, MDS Inc., (416) 675-6777
ext. 34721,
Copyright
Mds (NYSE:MDZ)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Mds (NYSE:MDZ)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Mds (New York Stock Exchange): 0 recent articles
Plus d'articles sur Mds